Evidence map›Paper›PMID 33479913›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2021

Purification and Immunophenotypic Characterization of Human CD24

Rowa Y Alhabbab, Giovanna Lombardi

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Rowa Y AlhabbabFacility of Applied Medical Sciences, Medical Laboratory Technology Department, Immunology Group, King Abdulaziz University, Jeddah, Saudi Arabia. rymalhabbab@kau.edu.sa.
Giovanna LombardiMRC Centre for Transplantation, School of Immunology & Mucosal Biology, King's College London, London, UK. giovanna.lombardi@kcl.ac.uk.
King Abdulaziz University · SAKing's College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transplantation is still the treatment of choice for organ failure; however, allograft induces inflammatory immune responses that require immunosuppressive treatment. The role of regulatory B cells (Bregs) in downregulating inflammation has been reported to be significant in several diseases including transplant rejection. Many reports have analyzed different B-cell subpopulations, including Bregs, in tolerant, stable, and rejecting transplant recipients as well as the influence of immunosuppressant on the frequencies and functions of the different B-cell subsets. In this chapter, the key techniques required to investigate human Breg frequencies and functions in transplant patients are discussed.

Indexed as

ADP-ribosyl Cyclase 1B-Lymphocytes, RegulatoryCD24 AntigenCell CountCell ProliferationFemaleHumansImmunophenotypingImmunosuppressive AgentsInterleukin-10MaleTumor Necrosis Factor Receptor Superfamily, Member 7ADP-ribosyl Cyclase 1CD24 AntigenImmunosuppressive AgentsInterleukin-10Tumor Necrosis Factor Receptor Superfamily, Member 7Breg frequencyBreg functionCD24hiCD27+ BregsCD24hiCD38hi BregsHuman BregsTransplantation

Identifiers

PMID33479913
OpenAlexW3122197558

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.